智通财经APP讯，白云山(00874)发布公告，近日，该公司分公司广州白云山医药集团股份有限公司白云山化学制药厂(以下简称“白云山化学制药厂”)收到国家药品监督管理局(以下简称“国家药监局”)签发的苹果酸舒尼替尼《化学原料药上市申请批准通知书》。
白云山化学制药厂本次获得化学原料药苹果酸舒尼替尼《化学原料药上市申请批准通知书》，表明该原料药已符合国家相关药品审评技术标准，可进行生产销售，有助于丰富白云山化学制药厂抗肿瘤类药品的种类，提升公司在抗肿瘤领域市场的竞争力。本次获得该药物《化学原料药上市申请批准通知书》，公司当期业绩无重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.